Elutia (ELUT) Competitors $0.89 +0.01 (+0.87%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$0.90 +0.01 (+1.03%) As of 10/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ELUT vs. MOLN, NKTX, CRDF, TVGN, BTMD, ONCY, ZYBT, ATOS, VIRI, and SCLXShould you be buying Elutia stock or one of its competitors? The main competitors of Elutia include Molecular Partners (MOLN), Nkarta (NKTX), Cardiff Oncology (CRDF), Tevogen Bio (TVGN), biote (BTMD), Oncolytics Biotech (ONCY), Zhengye Biotechnology (ZYBT), Atossa Genetics (ATOS), Virios Therapeutics (VIRI), and Scilex (SCLX). These companies are all part of the "pharmaceutical products" industry. Elutia vs. Its Competitors Molecular Partners Nkarta Cardiff Oncology Tevogen Bio biote Oncolytics Biotech Zhengye Biotechnology Atossa Genetics Virios Therapeutics Scilex Molecular Partners (NASDAQ:MOLN) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations. Does the media refer more to MOLN or ELUT? In the previous week, Elutia had 3 more articles in the media than Molecular Partners. MarketBeat recorded 7 mentions for Elutia and 4 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.79 beat Elutia's score of 0.58 indicating that Molecular Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Molecular Partners 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Elutia 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, MOLN or ELUT? Molecular Partners has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, Elutia has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500. Do analysts recommend MOLN or ELUT? Molecular Partners currently has a consensus target price of $8.00, suggesting a potential upside of 114.42%. Elutia has a consensus target price of $7.00, suggesting a potential upside of 682.30%. Given Elutia's stronger consensus rating and higher probable upside, analysts clearly believe Elutia is more favorable than Molecular Partners.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Elutia 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is MOLN or ELUT more profitable? Molecular Partners has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Molecular PartnersN/A -50.66% -45.13% Elutia -90.01%N/A -54.08% Which has better earnings and valuation, MOLN or ELUT? Elutia has higher revenue and earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMolecular Partners$5.65M26.67-$61.39M-$2.08-1.79Elutia$23.68M1.60-$53.95M-$1.06-0.84 Do insiders & institutionals have more ownership in MOLN or ELUT? 26.6% of Molecular Partners shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 5.9% of Molecular Partners shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. SummaryElutia beats Molecular Partners on 11 of the 16 factors compared between the two stocks. Get Elutia News Delivered to You Automatically Sign up to receive the latest news and ratings for ELUT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELUT vs. The Competition Export to ExcelMetricElutiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.61M$3.37B$6.11B$10.46BDividend YieldN/A2.30%5.73%4.77%P/E Ratio-0.8422.7785.3627.36Price / Sales1.60467.74602.77132.73Price / CashN/A46.7037.4661.86Price / Book-0.6810.5512.426.81Net Income-$53.95M-$52.58M$3.32B$276.80M7 Day Performance1.39%0.09%0.57%0.42%1 Month Performance-24.17%15.61%10.52%7.86%1 Year Performance-76.51%15.13%72.99%41.24% Elutia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELUTElutia3.1592 of 5 stars$0.89+0.9%$7.00+682.3%-76.7%$37.61M$23.68M-0.84180MOLNMolecular Partners1.4841 of 5 stars$3.70-1.5%$8.00+116.5%-24.6%$149.20M$5.65M-1.78180Analyst ForecastGap UpNKTXNkarta2.4046 of 5 stars$2.09-3.0%$13.60+552.3%-33.8%$148.09MN/A-1.41140CRDFCardiff Oncology2.5523 of 5 stars$2.20-0.2%$10.63+384.1%-9.7%$146.03M$545K-2.5220TVGNTevogen Bio2.9813 of 5 stars$0.72+11.6%$10.00+1,281.2%-44.9%$143.20MN/A-3.833News CoverageBTMDbiote2.3574 of 5 stars$2.85-2.1%$6.00+110.6%-46.1%$140.66M$197.19M3.16194ONCYOncolytics Biotech1.9217 of 5 stars$1.35-0.7%$5.00+270.4%-2.4%$135.49MN/A-5.0030ZYBTZhengye BiotechnologyN/A$2.86-0.7%N/AN/A$134.91M$25.53M0.00278News CoverageAnalyst ForecastGap DownATOSAtossa Genetics2.5966 of 5 stars$1.01+0.5%$6.25+521.9%-26.6%$129.82MN/A-4.378News CoverageAnalyst DowngradeGap UpVIRIVirios TherapeuticsN/A$6.69+4.4%$5.00-25.3%+70.5%$128.84MN/A-24.785News CoverageSCLXScilex2.2368 of 5 stars$18.41+9.5%$455.00+2,371.5%-49.3%$126.33M$56.59M-0.6380 Related Companies and Tools Related Companies MOLN Competitors NKTX Competitors CRDF Competitors TVGN Competitors BTMD Competitors ONCY Competitors ZYBT Competitors ATOS Competitors VIRI Competitors SCLX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELUT) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elutia Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elutia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
